Sugi Predict

Sugi Predict / Compounds / SCHEMBL457886

SCHEMBL457886

SCHEMBL457886

C#CNC(Cc1ccccc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MME P08473 4/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.51
▸ NAALAD2 Q9Y3Q0 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ MMP2 P08253 5/20 0.49
▸ MMP9 P14780 4/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ ADAMTS4 O75173 1/20 0.49
▸ FOLH1 Q04609 1/20 0.49
▸ ACE P12821 2/20 0.48
▸ CPA1 P15085 2/20 0.48
▸ ACE2 Q9BYF1 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL457887 1.00 MME (0.53) MMENPSR1NAALAD2CYP1A2MMP2
SCHEMBL5148295 0.92 GNPAT (0.49) MMENPSR1NAALAD2CYP1A2MMP2
SCHEMBL1833191 0.84 MME (0.54) MMENPSR1NAALAD2CYP1A2MMP2
SCHEMBL1792999 0.84 MME (0.54) MMENPSR1NAALAD2CYP1A2MMP2
SCHEMBL23249767 0.82 MME (0.57) MMENPSR1NAALAD2CYP1A2MMP2
SCHEMBL2492587 0.82 MME (0.57) MMENPSR1NAALAD2CYP1A2MMP2
SCHEMBL2492588 0.82 MME (0.57) MMENPSR1NAALAD2CYP1A2MMP2
Hydrochloric Acid SCHEMBL7300980 0.81 MME (0.55) MMENPSR1NAALAD2CYP1A2MMP2
Hydrochloric Acid SCHEMBL8838224 0.81 MME (0.55) MMENPSR1NAALAD2CYP1A2MMP2
SCHEMBL308606 0.79 CYP1A2 (0.60) MMENPSR1NAALAD2CYP1A2MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970408-B1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC (US) 2018-01-10 — — EP claimed
US-20160024159-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 AMGEN INC. (US) 2016-01-28 — — US claimed
EP-2970408-A2 POTENT AND SELECTIVE INHIBITORS OF Nav1.7 Amgen Inc. (US) 2016-01-20 — — EP claimed
WO-2014165277-A2 POTENT AND SELECTIVE INHIBITORS OF Nav1.7 AMGEN INC. (US) 2014-10-09 — — WO claimed
EP-4588521-A2 POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS VAXCYTE, INC. (US) 2025-07-23 — — EP disclosed
WO-2025076210-A1 CHLAMYDIA VACCINE COMPOSITIONS VAXCYTE, INC. (US) 2025-04-10 — — WO disclosed
EP-4483896-A2 IMPROVEMENTS IN IMMUNOGENIC CONJUGATES VAXCYTE, INC. (US) 2025-01-01 — — EP disclosed
CN-119053342-A Multispecific antibodies for affinity receptor cross-linking and immunomodulation 礼进生物医药控股有限公司 2024-11-29 — — CN disclosed
US-20240383842-A1 METHODS OF PREPARING CHIRAL AMINO ACIDS Laboratory for Synthetic Chemistry and Chemical Biology Limited (CN) 2024-11-21 — — US disclosed
CN-114316061-B Bispecific antibodies against plasma kallikrein and factor XII 武田药品工业株式会社 2024-11-01 — — CN disclosed
US-20240358823-A1 CONJUGATED VACCINE CARRIER PROTEINS VAXCYTE, INC. 2024-10-31 — — US disclosed
US-20240342274-A1 POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS VAXCYTE, INC. 2024-10-17 — — US disclosed
US-20080214439-A1 AMINO ACID SUBSTITUTED MOLECULES ALLOZYNE, INC. (US) 2008-09-04 — — US disclosed
US-20080200641-A1 AMINO ACID SUBSTITUTED MOLECULES ALLOZYNE, INC. (US) 2008-08-21 — — US disclosed
EP-1928502-A2 MODIFIED FC MOLECULES Amgen, Inc (US) 2008-06-11 — — EP disclosed
US-20080125347-A1 AMINO ACID SUBSTITUTED MOLECULES ALLOZYNE, INC. (US) 2008-05-29 — — US disclosed
US-20080096819-A1 Amino acid substituted molecules ALLOZYNE, INC. (US) 2008-04-24 — — US disclosed
WO-2007130453-A2 NON-NATURAL AMINO ACID SUBSTITUTED POLYPEPTIDES ALLOZYNE, INC. (US) 2007-11-15 — — WO disclosed
WO-2007103307-A2 SITE-SPECIFIC INCORPORATION OF AMINO ACIDS INTO MOLECULES CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2007-09-13 — — WO disclosed
WO-2007022070-A2 MODIFIED FC MOLECULES AMGEN INC. (US) 2007-02-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240342274-A1 POLYPEPTIDE-ANTIGEN CONJUGATES WITH NON-NATURAL AMINO ACIDS CD74, DNPEP, NGLY1 MME 511/4885NPSR1 469/4885NAALAD2 59/4885
US-20240383842-A1 METHODS OF PREPARING CHIRAL AMINO ACIDS BCAT1, BCAT2, ME1 MME 147/4885NPSR1 4134/4885NAALAD2 142/4885
US-20080096819-A1 Amino acid substituted molecules BCAT2, DNPEP, PTMS MME 404/4885NPSR1 406/4885NAALAD2 84/4885
US-20080214439-A1 AMINO ACID SUBSTITUTED MOLECULES BCAT2, DNPEP, PTMS MME 404/4885NPSR1 406/4885NAALAD2 84/4885
US-20080200641-A1 AMINO ACID SUBSTITUTED MOLECULES BCAT2, DNPEP, PTMS MME 404/4885NPSR1 406/4885NAALAD2 84/4885
US-20240358823-A1 CONJUGATED VACCINE CARRIER PROTEINS CD74, LY96, ASNS MME 1636/4885NPSR1 1532/4885NAALAD2 180/4885
US-20160024159-A1 POTENT AND SELECTIVE INHIBITORS OF NAV1.7 SCN7A, SCN9A, SCN1A MME 1321/4885NPSR1 732/4885NAALAD2 3643/4885
US-20080125347-A1 AMINO ACID SUBSTITUTED MOLECULES BCAT2, DNPEP, PTMS MME 404/4885NPSR1 406/4885NAALAD2 84/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.